Calls for papers
-
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study’s primary endpoint.… Read more . . .
-
Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015.… Read more . . .
-
The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for… Read more . . .
-
The 2nd article in a 3-part series . . . Read more Read more . . .
-
Alexza Pharmaceuticals has announced the appointment of Michael S. Holfinger as Vice President, Manufacturing & Global Supply Chain Management. Holfinger was most recently Vice President, Manufacturing & CMC Development at Affymax. Alexza recently announced that… Read more . . .
-
Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin… Read more . . .
-
Italian aerosol device and filling machine company Coster Pharma has announced that its Type 3 Drug Master File (DMF) for two of its MDI valves to the FDA has been issued the DMF number 26960.… Read more . . .
-
Weeks after the conclusion of RDD Europe 2013 in Berlin, organizers RDD Online and Aptar Pharma are still wrapping up logistical loose ends and analyzing delegate feedback, says Pierre Carlotti of Aptar Pharma. . .… Read more . . .
-
Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s disease patients, the company… Read more . . .
-
Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland